NASDAQ$TVTX

Travere Therapeutics Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Travere Therapeutics reported financial results for the second quarter of 2021.

Travere Therapeutics reported net product sales of $54.6 million for the second quarter of 2021. The company is on track to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021. The pivotal PROTECT Study of sparsentan in IgA nephropathy is on track to report topline data from the interim 36-week proteinuria endpoint in August 2021.

  • The Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021.
  • The Phase 3 PROTECT Study of sparsentan in IgA nephropathy (IgAN) completed patient enrollment in the second quarter of 2021; topline data from the 36-week interim proteinuria analysis are on track for August 2021.
  • Net product sales for the second quarter 2021 were $54.6 million, compared to $48.4 million for the same period in 2020.
  • Cash, cash equivalents and marketable securities, as of June 30, 2021, totaled $522.8 million.

Headline financials

Total Revenue

$54.6M

Previous: $48.4M+12.8%
EPS (adj)

-$0.39

Previous: -$0.22-77.3%
Capital Expenditures

-$4.6M

Previous: -$518K-787.6%
Free Cash Flow

-$43.6M

Previous: -$26.6M-64.0%
Net Income

-$39M

Previous: -$26.1M-49.7%
Operating Income

-$35.3M

Previous: -$23.1M-52.8%
Gross Profit

$53M

Previous: $46.9M+12.8%
Cash & Equivalents

$83.3M

Previous: $237M-64.9%
Total Assets

$747M

Previous: $679M+10.0%
Stock-Based Comp

$6.86M

Previous: $5.56M+23.3%

Revenue & EPS history

Travere · Revenue · Quarterly

$54.6M

Q2 2021+12.8%vs Q2 2020
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Revenue by segment

Travere · $33.9M total across 2 segments · Q3 2023

  • Tiopronin products
    $25.9M+2.0%
  • FILSPARI
    $8.04M

Forward guidance

Travere Therapeutics expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 and anticipates topline efficacy data from the 36-week interim proteinuria endpoint analysis from the PROTECT Study in August 2021.

Tailwinds

  • Remain on-track to submit an application for conditional marketing authorization for FSGS in Europe later this year.
  • Adjusted U.S. timelines for FSGS and look forward to our upcoming Type A meeting with the FDA to further our collaborative discussions on the potential to stay on an accelerated approval pathway.
  • Looking forward to the upcoming topline results from our Phase 3 PROTECT Study of sparsentan in IgA nephropathy, which if successful, would contribute to the growing body of evidence for sparsentan in rare kidney disorders, and potentially support submissions for accelerated approval in the U.S. and conditional marketing authorization in Europe.
  • The DUPLEX Study is fully enrolled and is scheduled to continue as planned on a blinded basis to assess the confirmatory estimated glomerular filtration rate (eGFR) endpoint after 108 weeks of treatment.
  • Completed enrollment in the highest currently planned dosing cohort in the ongoing Phase 1/2 dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects of pegtibatinase in patients with classical HCU.

Headwinds

  • Risk that the FDA or EMA could disagree with the Company’s submission of an NDA under Subpart H for accelerated approval, or a Marketing Approval Application (“MAA”) under the CMA pathway.
  • Risk that the Phase 3 DUPLEX Study of sparsentan in FSGS will not demonstrate that sparsentan is safe or effective or serve as a basis for accelerated approval of sparsentan as planned.
  • Risk that the Phase 3 PROTECT Study of sparsentan in IgAN will not demonstrate that sparsentan is safe or effective or serve as the basis for accelerated approval of sparsentan as planned.
  • Risk that sparsentan will not be approved for efficacy, safety, regulatory or other reasons.
  • Risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-0.6%

Avg return

Earnings day

-1.3%

Avg return

5 days after

-0.3%

Avg return

30 days after

49%

25 / 51 earnings

Positive

+16.6%

Q3 2025

Best reaction

-16.7%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.8%-5.1%+2.8%
Q4 2025+3.1%+0.1%-8.4%
Q3 2025+16.6%+13.7%+19.4%
Q1 2025+1.6%-2.6%-27.6%
Q4 2024-6.8%-10.8%-12.9%
Q3 2024-1.1%-0.0%+5.9%
Q2 2024-5.7%-6.7%-0.7%
Q1 2024+7.8%+0.6%+25.1%
Q4 2023-0.6%+0.4%-9.2%
Q3 2023-4.7%-16.0%+30.3%
Q2 2023-6.6%-6.7%-10.5%
Q1 2023+5.6%+4.2%+19.7%
Q4 2022+6.9%+6.2%+0.0%
Q3 2022+3.1%+0.5%-12.4%
Q2 2022+16.0%+16.2%+13.5%
Q1 2022-14.2%-13.2%-6.4%
Q4 2021+2.9%+2.1%-3.3%
Q3 2021+10.0%+15.1%+10.8%
Q2 2021-2.4%+0.5%+52.7%
Q1 2021-16.6%-17.4%-41.2%
Q4 2020-5.3%-12.4%-19.0%
Q3 2020+1.6%+11.4%+18.1%
Q2 2020-1.6%-4.1%-4.3%
Q1 2020+7.6%+0.8%-0.9%
Q4 2019-16.7%-10.3%-21.4%
Q3 2019+4.4%+8.0%+20.7%
Q2 2019-11.4%-2.7%-34.0%
Q1 2019-7.9%-5.5%-2.7%
Q4 2018+5.6%+4.3%+7.7%
Q3 2018+0.6%+1.2%-4.4%
Q2 2018-4.4%-4.2%+2.4%
Q1 2018-5.2%-5.7%+11.6%
Q4 2017+5.4%+5.2%-5.8%
Q3 2017-13.4%-16.3%-17.1%
Q2 2017-0.1%+7.6%+15.8%
Q1 2017-4.4%-6.5%-7.1%
Q4 2016+1.5%-0.6%-13.2%
Q3 2016-4.3%-1.2%+8.5%
Q2 2016+1.4%-1.9%-13.6%
Q1 2016+5.2%
Q4 2015-2.8%
Q3 2015-10.0%
Q2 2015+13.0%
Q1 2015+5.8%
Q4 2014+9.5%
Q3 2014-14.4%
Q2 2014-6.2%
Q1 2014+4.9%
Q4 2013+8.4%
Q3 2013-5.8%
Q2 2012-9.9%
Q3 2012
Q1 2012
Q4 2012
Q3 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro